Kyverna Therapeutics Showcases Breakthrough CAR T Results in Autoimmune Diseases
I'm PortAI, I can summarize articles.
Kyverna Therapeutics Inc. showcased new clinical data for its CAR T cell therapy, Miv-cel (KYV-101), demonstrating significant improvements in patients with stiff person syndrome (SPS) across all trial endpoints. The therapy achieved a 100% elimination of off-label immunotherapies with a single dose and showed a manageable safety profile. The results pave the way for a Biologics License Application in early 2026, positioning Kyverna to be first-to-market in SPS, with plans to expand to myasthenia gravis. The company also reported a cash runway extending to 2028.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments